Wall St Engine(@wallstengine):FDA APPROVES MOUNJARO TO REDUCE CARDIOVASCULAR RISK Eli Lilly $LLY adds a cardiovascular indication for adults with type 2 diabetes at high risk of heart events. In the 13,299-patient SURPASS-CVOT trial, Mounjaro was non-inferior to Trulicity for cardiovascular death, heart attack and stroke, with a 0.92 hazard ratio. Superiority was not established.

Wall St Engine

@wallstengine

Fast, accurate, consistent stock market news, earnings highlights & more. By Brillinsight. Not financial advice.

Joined March 2022

931 Following 187.6K Followers

Wall St Engine@wallstengine

2026.08.28 11:01

FDA APPROVES MOUNJARO TO REDUCE CARDIOVASCULAR RISK Eli Lilly $LLY adds a cardiovascular indication for adults with type 2 diabetes at high risk of heart events. In the 13,299-patient SURPASS-CVOT trial, Mounjaro was non-inferior to Trulicity for cardiovascular death, heart attack and stroke, with a 0.92 hazard ratio. Superiority was not established.